Cooper AJ et al. Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management. Nat Rev Clin Oncol 2022;19(8):499-514. Abstract
Felip E et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398(10308):1344-57. Abstract
Fowler JB et al. Effect of participation in the EGFR resisters research summit on competence, performance, and professional productivity of young researchers. ASCO 2022;Abstract e23010.
Hsu K et al. Optimizing supportive care for patients with metastatic lung cancer in the era of precision oncology. ASCO 2022;Abstract TPS12150.
Jänne PA et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov 2022;12(1):74-89. Abstract
Meador CB et al. Targeting EGFR exon 20 insertions in non-small cell lung cancer: Recent advances and clinical updates. Cancer Discov 2021;11(9):2145-57. Abstract
Neal JW et al. Randomized phase II study of 3 months or 2 years of adjuvant afatinib in patients with surgically resected stage I-III EGFR-mutant non-small-cell lung cancer. JCO Precis Oncol 2021;5:325-32. Abstract
Piotrowska Z et al. Complete evaluation of resistance mechanisms to first-line osimertinib requires tissue biopsy. ASCO 2022;Abstract e21154.
Piper-Vallillo AJ et al. High-dose osimertinib for CNS progression in EGFR+ NSCLC: A multi-institutional experience. JTO Clin Res Rep 2022;3(6):100328. Abstract
Rolfo C et al. Liquid biopsy for advanced NSCLC: A consensus statement from the International Association for the Study of Lung Cancer. J Thorac Oncol 2021;16(10):1647-62. Abstract
Tan DSW et al. Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. Eur J Cancer 2022;172:276-86. Abstract
White MN et al. Chemotherapy plus immunotherapy versus chemotherapy plus bevacizumab versus chemotherapy alone in EGFR-mutant NSCLC after progression on osimertinib. Clin Lung Cancer 2022;23(3):e210-21. Abstract
White MN et al. Combining osimertinib with chemotherapy in EGFR-mutant NSCLC at progression. Clin Lung Cancer 2021;22(3):201-9. Abstract